Summit Therapeutics PLC says c-difficile trial slowed by coronavirus pandemic disruption
US infectious diseases company BARDA is supporting to fund the trial with a grant truly worth up to $72.5mln.
(NASDAQ:SMMT) claimed it had recruited 252 individuals into its period III trial for its c-difficile (CDI) therapy at the finish of March, although the coronavirus outbreak has slowed enrolment.
The Ri-CoDIFy clinical trials are testing the superiority of Summit’s drug Ridinilazole about the latest normal of treatment, Vancomycin, but since of the uncertainty encompassing the coronavirus outbreak, it has withdrawn the timeline for its completion.
Summit additional that in the light-weight of the coronavirus pandemic, staff are currently working remotely with its very own laboratory facilities temporarily closed.
US infectious diseases company BARDA is supporting to fund the trial with a grant truly worth up to $72.5mln.
Losses for the eleven months to December have been £22mln whilst the corporation had money of £48.4mln at the finish of the calendar year.
NO Investment decision Guidance
The Company is a publisher. You comprehend and concur that no written content revealed on the Web site constitutes a advice that any particular security, portfolio of securities, transaction, or financial commitment strategy is…
In exchange for publishing companies rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the marketing by the Company of Summit Therapeutics PLC in any Content on the Web site, the Company…
FOR OUR Comprehensive DISCLAIMER Simply click Below
